Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $929000.0.

  • Regenxbio's Other Accumulated Expenses rose 1804.32% to $929000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $929000.0, marking a year-over-year increase of 1804.32%. This contributed to the annual value of $649000.0 for FY2024, which is 4170.31% up from last year.
  • According to the latest figures from Q3 2025, Regenxbio's Other Accumulated Expenses is $929000.0, which was up 1804.32% from $736000.0 recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Other Accumulated Expenses ranged from a high of $999000.0 in Q1 2023 and a low of $122000.0 during Q1 2021
  • In the last 5 years, Regenxbio's Other Accumulated Expenses had a median value of $746000.0 in 2022 and averaged $694368.4.
  • Over the last 5 years, Regenxbio's Other Accumulated Expenses had its largest YoY gain of 36344.09% in 2021, and its largest YoY loss of 5864.41% in 2021.
  • Over the past 5 years, Regenxbio's Other Accumulated Expenses (Quarter) stood at $744000.0 in 2021, then grew by 0.27% to $746000.0 in 2022, then plummeted by 38.61% to $458000.0 in 2023, then soared by 41.7% to $649000.0 in 2024, then soared by 43.14% to $929000.0 in 2025.
  • Its last three reported values are $929000.0 in Q3 2025, $736000.0 for Q2 2025, and $779000.0 during Q1 2025.